

Daniela A Bota

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7027957/publications.pdf>

Version: 2024-02-01

124
papers

4,507
citations

172207

29
h-index

106150

65
g-index

129
all docs

129
docs citations

129
times ranked

6713
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 290-296.	0.7	5
2	Altered Retrograde Signaling Patterns in Breast Cancer Cells Cybrids with H and J Mitochondrial DNA Haplogroups. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6687.	1.8	3
3	Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 34-46.	157.7	10
4	Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 507-513.	2.8	37
5	Cognitive complications of cancer and cancer-related treatments – Novel paradigms. <i>Neuroscience Letters</i> , 2021, 749, 135720.	1.0	8
6	Exploring the role and clinical implications of proteasome inhibition in medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29168.	0.8	1
7	Abstract 331: Characterization of neoepitope (neoE)-specific T cells from peripheral blood for adoptive neoTCR-T cell therapy for patients with breast cancer (bc) or ovarian cancer (oc). , 2021, , .		0
8	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.4	15
9	952...Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma. , 2021, 9, A1001-A1001.		2
10	DDRE-50. INVESTIGATING THE ROLE OF LonP1 IN GLIOBLASTOMA TUMOR PROGRESSION. <i>Neuro-Oncology</i> , 2021, 23, vi85-vi85.	0.6	0
11	333...Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A359-A359.		0
12	331...Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma. , 2021, 9, A357-A357.		0
13	336...Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma. , 2021, 9, A362-A362.		0
14	DDRE-31. MITOCHONDRIAL TRAFFICKING AS A TARGET FOR GBM THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi81-vi81.	0.6	0
15	NCMP-13. ID8 OVARIAN CANCER MOUSE MODEL MIMICS NEUROLOGICAL SEQUELAE OF OVARIAN CANCER IN WOMEN. <i>Neuro-Oncology</i> , 2021, 23, vi149-vi149.	0.6	0
16	CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2021, 23, vi60-vi60.	0.6	1
17	335...Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A361-A361.		0
18	332...Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma. , 2021, 9, A358-A358.		0

#	ARTICLE	IF	CITATIONS
19	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	0.6	0
20	DDRE-38. MAGMAS INHIBITION IN MEDULLOBLASTOMA CELL CULTURES AND PATIENT-DERIVED XENOGRFT MODELS: POTENTIAL THERAPEUTIC IMPLICATIONS. <i>Neuro-Oncology</i> , 2021, 23, vi82-vi82.	0.6	0
21	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. <i>JAMA Oncology</i> , 2020, 6, 1939.	3.4	84
22	Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy. <i>American Journal of Therapeutics</i> , 2020, 27, e142-e150.	0.5	11
23	A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. <i>Frontiers in Neurology</i> , 2020, 11, 373.	1.1	11
24	Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons. <i>Mitochondrion</i> , 2020, 52, 56-66.	1.6	18
25	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1586-1594.	3.2	103
26	Development and external validation of a prognostic tool for COVID-19 critical disease. <i>PLoS ONE</i> , 2020, 15, e0242953.	1.1	19
27	Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups. <i>PeerJ</i> , 2020, 8, e9908.	0.9	8
28	DDRE-22. NOVEL LonP1 INHIBITORS FOR TARGETING GLIOMA STEM CELLS. <i>Neuro-Oncology</i> , 2020, 22, ii66-ii66.	0.6	0
29	154â€¦Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors. , 2020, , .		0
30	EXTH-19. EVALUATING THE ANTI-TUMOR EFFECT OF A NOVEL THERAPEUTIC AGENT, MAGMAS INHIBITOR, IN MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii90-ii91.	0.6	1
31	CTIM-26. PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii38-ii39.	0.6	0
32	NCMP-16. THE ROLE OF p38 AND JNK MAPK PATHWAYS IN CISPLATIN CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENT. <i>Neuro-Oncology</i> , 2020, 22, ii126-ii126.	0.6	0
33	RTID-04. A RANDOMIZED PHASE II TRIAL TO COMPARE THE EFFICACY OF STANDARD VERSUS COMBINATION THERAPY (PERAMPANEL, MEMANTINE PLUS STANDARD) IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GBM-A STUDY DESIGN. <i>Neuro-Oncology</i> , 2020, 22, ii194-ii194.	0.6	1
34	319â€¦Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. , 2020, , .		0
35	CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii34-ii34.	0.6	0
36	RTID-03. A PHASE I CLINICAL TRIAL TO EVALUATE MTD OF PERAMPANEL AND MEMANTINE IN COMBINATION WITH STANDARD CHEMORADIO THERAPY FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GBM â€œA STUDY DESIGN. <i>Neuro-Oncology</i> , 2020, 22, ii193-ii194.	0.6	1

#	ARTICLE	IF	CITATIONS
37	European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. <i>Frontiers in Oncology</i> , 2019, 9, 640.	1.3	21
38	Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging. <i>Cancers</i> , 2019, 11, 829.	1.7	75
39	RARE-36. BORTEZOMIB WOKE UP A PATIENT WITH ANTI-NMDA RECEPTOR ENCEPHALITIS REFRACTORY TO STANDARD THERAPY AND LONG TERM FOLLOW-UP. <i>Neuro-Oncology</i> , 2019, 21, vi229-vi229.	0.6	0
40	LS1 PRACTICAL APPLICATION AND UNDERLYING BIOLOGY OF TUMOR TREATING FIELDS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii1-ii1.	0.4	0
41	Magmas inhibition as a potential treatment strategy in malignant glioma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 267-276.	1.4	9
42	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019, 6, 249-258.	1.0	52
43	Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. , 2019, , .		1
44	Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. , 2019, , .		0
45	Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. <i>CNS Oncology</i> , 2018, 7, CNS09.	1.2	16
46	Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. <i>American Journal of Roentgenology</i> , 2018, 210, 30-38.	1.0	52
47	Somatic SMARCB1 Mutation in Sporadic Multiple Meningiomas: Case Report. <i>Frontiers in Neurology</i> , 2018, 9, 919.	1.1	3
48	ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi13.	0.6	0
49	10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, S2-S2.	0.3	1
50	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 ⁺ T-lymphocyte counts. <i>CNS Oncology</i> , 2018, 7, CNS22.	1.2	49
51	Therapeutic Immunization against Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2540.	1.8	14
52	CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. <i>Cell Stem Cell</i> , 2018, 22, 801-805.	5.2	5
53	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	1.8	376
54	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. <i>American Journal of Neuroradiology</i> , 2018, 39, 1201-1207.	1.2	323

#	ARTICLE	IF	CITATIONS
55	Chemotherapy-related cognitive dysfunction and effects on quality of life in gynecologic cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018, 3, 19-26.	0.6	12
56	Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic. <i>Translational Cancer Research</i> , 2018, 7, S460-S462.	0.4	3
57	The importance of brain-derived neurotrophic factor in maintaining brain health during and after cancer treatments. <i>Oncolog-Hematolog Ro</i> , 2018, 1, 22.	0.0	0
58	Multiscale modeling of glioblastoma. <i>Translational Cancer Research</i> , 2018, 7, S96-S98.	0.4	0
59	Cancerâ€™ Incidence, prevalence and mortality in the oldest-old. A comprehensive review. <i>Mechanisms of Ageing and Development</i> , 2017, 164, 113-126.	2.2	63
60	Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. <i>Free Radical Biology and Medicine</i> , 2017, 102, 274-286.	1.3	110
61	3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy. <i>Cancer Research</i> , 2017, 77, 4171-4184.	0.4	35
62	Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma. <i>CNS Oncology</i> , 2017, 6, 89-94.	1.2	0
63	First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report. <i>CNS Oncology</i> , 2017, 6, 11-18.	1.2	10
64	Diminished stress resistance and defective adaptive homeostasis in age-related diseases. <i>Clinical Science</i> , 2017, 131, 2573-2599.	1.8	32
65	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
66	Expression of the BRAF L597Q mutation in sporadic neurofibromas of the upper extremity. <i>Experimental and Molecular Pathology</i> , 2017, 103, 276-278.	0.9	2
67	Systemic cisplatin exposure during infancy and adolescence causes impaired cognitive function in adulthood. <i>Behavioural Brain Research</i> , 2017, 319, 200-206.	1.2	25
68	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. <i>CNS Oncology</i> , 2017, 6, 29-43.	1.2	34
69	NTOX-04. INVESTIGATION OF N-ACETYLCYSTEINE FOR THE PREVENTION OF CISPLATIN CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENTS. <i>Neuro-Oncology</i> , 2017, 19, vi165-vi166.	0.6	0
70	MNGI-12. AÂRETROSPECTIVE INTERVENTIONAL COHORT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SANDOSTATIN LAR (OCTREOTIDE ACETATE) FOR THE TREATMENT OF MENINGIOMAS IN ADULT PATIENTS. <i>Neuro-Oncology</i> , 2017, 19, vi134-vi134.	0.6	2
71	ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM). <i>Neuro-Oncology</i> , 2017, 19, vi16-vi16.	0.6	4
72	NCOG-10. N-ACETYLCYSTEINE (NAC) TREATMENT CAN REVERSE CISPLATIN â€™ INDUCED COGNITIVE DAMAGE IN RATS. <i>Neuro-Oncology</i> , 2016, 18, vi121-vi121.	0.6	0

#	ARTICLE	IF	CITATIONS
73	NIMG-61. PATTERNS OF GLIOBLASTOMA RECURRENCE IN LOW FIELD INTENSITY REGIONS DURING TTFIELDS TREATMENT. <i>Neuro-Oncology</i> , 2016, 18, vi137-vi138.	0.6	0
74	ACTR-41. AÂPHASE II, SINGLE ARM STUDY OF OPTUNEÂ® IN BEVACIZUMAB-NAIVE SUBJECTS WITH RECURRENT WHO GRADE III MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, vi11-vi11.	0.6	1
75	ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY. <i>Neuro-Oncology</i> , 2016, 18, vi13-vi13.	0.6	0
76	ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2016, 18, vi17-vi17.	0.6	2
77	NIMG-23. DEVELOPMENT OF PRACTICE ALGORITHMS TO GUIDE TREATMENT PLANNING WITH TTFIELDS FOR THE MANAGEMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi129-vi129.	0.6	0
78	The effects of sequential treatments on hippocampal volumes in malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2016, 129, 433-441.	1.4	14
79	Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders. <i>Free Radical Biology and Medicine</i> , 2016, 100, 188-198.	1.3	129
80	ATIM-20. AÂRANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS. <i>Neuro-Oncology</i> , 2016, 18, vi22-vi22.	0.6	1
81	Cognitive Impairment in Survivors of Adolescent and Early Young Adult Onset Non-CNS Cancers: Does Chemotherapy Play a Role?. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 226-231.	0.7	18
82	Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. <i>Neuro-Oncology</i> , 2016, 18, 840-848.	0.6	105
83	Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2037-2037.	0.8	4
84	Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma. <i>Oncotarget</i> , 2016, 7, 77457-77467.	0.8	31
85	Abstract 3069: Investigation of pharmacodynamic and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma. , 2016, , .		0
86	Abstract 4782: Cisplatin induces mitochondrial damage and hippocampal neurotoxicity: a potential mechanism for chemotherapy-related cognitive impairment. , 2016, , .		0
87	Corrigendum to "Clinical Practice Experience With Novo TTF-100Aâ„¢ System for Glioblastoma: The Patient Registry Dataset (PRiDe)" Seminars in Oncology, 2015, 42, e33-e43.	0.8	2
88	Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 35-39.	0.8	30
89	First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. <i>Vaccine</i> , 2015, 33, 2690-2696.	1.7	41
90	Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. , 2015, 19, 41-46.		10

#	ARTICLE	IF	CITATIONS
91	Epidemiology of Central Nervous System Metastases. , 2014, , 11-23.		3
92	Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. Journal of Neuro-Oncology, 2014, 120, 473-481.	1.4	23
93	Alternating Electric Fields Therapy for Recurrent Glioblastoma - Novottf-100A System: Updated Outcomes and Toxicity Based on the Analysis of Patient Registry Data. Annals of Oncology, 2014, 25, iv137.	0.6	0
94	The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Human Vaccines and Immunotherapeutics, 2014, 10, 3322-3331.	1.4	26
95	Low-doses of cisplatin injure hippocampal synapses: A mechanism for "chemo" brain?. Experimental Neurology, 2014, 255, 137-144.	2.0	81
96	Therapeutic Targeting of Malignant Glioma. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1075-1084.	0.9	7
97	Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab. Reviews in Health Care, 2014, 5, 23-32.	0.1	11
98	Special Medical Conditions Associated with Catatonia in the Internal Medicine Setting: Hyponatremia-Inducing Psychosis and Subsequent Catatonia. , 2014, 18, 78-81.		14
99	Abstract 1809: Marizomib (NPI-0052) activity as a single agent in malignant glioma. , 2014, , .		1
100	Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Journal of Neurosurgery, 2013, 119, 1415-1423.	0.9	53
101	Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. Journal of Neurosurgery, 2013, 118, 1183-1187.	0.9	59
102	The evaluation and treatment of primary intraocular lymphoma. Journal of Cancer Therapeutics & Research, 2013, 2, 15.	1.2	2
103	Antivascular Endothelial Growth Factor Antibody for Treatment of Glioblastoma Multiforme. , 2013, 17, 68-74.		3
104	Undifferentiated Sarcoma Induced by BCNU (1,3-bis(2-chloroethyl) -1-nitrosourea) Wafers. Journal of Interdisciplinary Histopathology, 2013, 1, 163.	0.2	2
105	The use of intravitreal rituximab in conjunction with systemic temozolomide and intravenous rituximab for the treatment of primary intraocular lymphoma. Hematology and Leukemia, 2013, 1, 1.	0.2	0
106	Recurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment. Journal of Interdisciplinary Histopathology, 2013, 1, 217.	0.2	0
107	Two Patients With Brain Tumors Who Received Bevacizumab and Radiotherapy: Optic Neuropathy and Quality-of-Life Issues. Journal of the Advanced Practitioner in Oncology, 2013, 4, 252-6.	0.2	2
108	Glioma Big Potassium Channel Expression in Human Cancers and Possible T Cell Epitopes for Their Immunotherapy. Journal of Immunology, 2012, 189, 2625-2634.	0.4	24

#	ARTICLE	IF	CITATIONS
109	Epidemiology of Central Nervous System Metastases. <i>Progress in Neurological Surgery</i> , 2012, 25, 13-29.	1.3	41
110	Access to specialized treatment by adult Hispanic brain tumor patients: findings from a single-institution retrospective study. <i>Community Oncology</i> , 2012, 9, 283-288.	0.2	1
111	Impairment of Lon-Induced Protection Against the Accumulation of Oxidized Proteins in Senescent Wi-38 Fibroblasts. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011, 66A, 1178-1185.	1.7	49
112	Primary leptomeningeal plasmablastic lymphoma. <i>Journal of Neuro-Oncology</i> , 2011, 104, 835-838.	1.4	13
113	Pulmonary metastases in patients with recurrent, treatment-resistant meningioma. <i>Cancer</i> , 2011, 117, 4506-4511.	2.0	22
114	Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. <i>Neurology</i> , 2011, 76, 1126-1134.	1.5	97
115	Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype. <i>Cancer Biology and Therapy</i> , 2011, 11, 307-310.	1.5	5
116	Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib. <i>Journal of Neuro-Oncology</i> , 2010, 99, 123-128.	1.4	6
117	Acute Methotrexate Neurotoxicity with Choreiform Movements and Focal Neurological Deficits: A Case Report. <i>Southern Medical Journal</i> , 2009, 102, 1071-1074.	0.3	14
118	Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 707-15.	0.9	69
119	The Dynamics of Insight in the Prodrome of Schizophrenia. <i>CNS Spectrums</i> , 2006, 11, 355-362.	0.7	19
120	Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. <i>Free Radical Biology and Medicine</i> , 2005, 38, 665-677.	1.3	194
121	Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress. <i>FEBS Letters</i> , 2002, 532, 103-106.	1.3	213
122	Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. <i>Nature Cell Biology</i> , 2002, 4, 674-680.	4.6	509
123	Protein degradation in mitochondria: implications for oxidative stress, aging and disease. <i>Mitochondrion</i> , 2001, 1, 33-49.	1.6	92
124	A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3